Avalyn Pharma announced it will present two studies at the American Thoracic Society 2026 conference, focusing on patient experiences with its inhaled therapy AP01 and supportive care in pulmonary fibrosis. The presentations highlight Avalyn's commitment to incorporating patient and caregiver feedback to improve treatment usability and healthcare support. These findings support Avalyn's ongoing clinical trials of inhaled antifibrotic drugs aimed at improving lung function and reducing side effects in pulmonary fibrosis patients. The company aims to set a new standard of care with its inhaled therapies targeting rare respiratory diseases.
Following Shell's interim dividend payment for Q1 2026 on June 29, several senior executives, including CEO Wael Sawan and CFO Sinead Gorman, acquired shares through dividend reinvestment plans. These shares were obtained in respect of shares previou...
The global aliphatic hydrocarbon solvents and thinners market is projected to grow from $5.26 billion in 2026 to $6.81 billion by 2032, at a CAGR of 4.4%. Growth is fueled by rising demand in coatings, adhesives, and industrial maintenance, with mine...
The global data center semiconductor market is projected to grow from $86.8 billion in 2024 to $265.8 billion by 2029, driven by rising demand for AI-powered servers. The power stage segment will dominate due to its critical role in efficient power d...
The data center direct-to-chip cooling market is projected to grow from $3.33 billion in 2026 to $17.31 billion by 2032, at a CAGR of 26.5%. This growth is driven by the need for precise thermal management in advanced computing, especially for edge c...
The global environmental DNA (eDNA) market is projected to expand from $1.63 billion in 2026 to $5.61 billion by 2031, growing at a 10.2% CAGR. This growth is driven by advanced, non-invasive testing methods that detect species through genetic materi...
